SML0596
雷尼酸锶
≥98% (HPLC)
别名:
2-[N,N-Di(carboxymethyl)amino]-3-cyano-4-carboxymethylthiophene-5-carboxylic acid strontium salt, 5-[Bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid, strontium salt, Distrontium renelate, Ranelic acid strontium salt
SMILES string
[Sr+2].[Sr+2].[s]1c(c(c(c1C(=O)[O-])CC(=O)[O-])C#N)N(CC(=O)[O-])CC(=O)[O-]
InChI
1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4
InChI key
XXUZFRDUEGQHOV-UHFFFAOYSA-J
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 1 mg/mL, clear (warmed)
storage temp.
−20°C
Quality Level
相关类别
Biochem/physiol Actions
Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while activating gene expression in osteoblasts. While its exact mechanism of action is unknown, one hypothesis is that both anabolic and anti-catabolic activities may involve antagonizing nuclear factor-KB (NF-KB) activation in bone cells. Strontium ranelate has been shown to inhibit the receptor activator of NF-KB ligand (RANKL)-induced nuclear translocation of NF-KB and activator protein-1. Strontium ranelate has been used clinically for the treatment of osteoporosis and a recent multinational study indicates the drug can also be used to treat osteoarthritis.
Strontium ranelate is a dual action bone agent (DABA); inhibitor of bone resorption and stimulator of bone formation.
Features and Benefits
This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持